What are the indications, dosing regimen, common side effects, and precautions for Remeron (mirtazapine)?

Remeron (Mirtazapine): Clinical Overview

Remeron (mirtazapine) is FDA-approved for major depressive disorder, with a starting dose of 15 mg nightly at bedtime, titrated up to 15-45 mg/day based on response, and is particularly valuable in older adults and patients with comorbid insomnia or weight loss. 1

Primary Indication

• Major depressive disorder is the FDA-approved indication for mirtazapine 1
• Mirtazapine is considered a preferred antidepressant for older adults (along with citalopram, escitalopram, sertraline, venlafaxine, and bupropion) due to its favorable adverse effect profile in this population 2
• The drug demonstrates comparable efficacy to SSRIs and tricyclic antidepressants for treating depression 2, 3

Dosing Regimen

Initial dosing:

• Start at 15 mg once daily, preferably in the evening before sleep 1
• This is the standard starting dose for all patients 1

Dose titration:

• Patients not responding to 15 mg may benefit from increases up to a maximum of 45 mg/day 1
• The effective dose range is generally 15-45 mg/day 1
• Do not change doses more frequently than every 1-2 weeks due to the 20-40 hour elimination half-life 1

Special populations:

• Elderly patients and those with renal or hepatic impairment require dose reduction (approximately 50% of standard adult starting dose) due to reduced clearance and increased plasma levels 2, 1

Maintenance treatment:

• Continue for at least 4 months after first episode of major depression 2
• Patients with recurrent depression may benefit from prolonged treatment 2
• When discontinuing, taper gradually over several weeks rather than stopping abruptly to minimize withdrawal symptoms 1

Mechanism of Action

Mirtazapine has a unique dual mechanism as a noradrenergic and specific serotonergic antidepressant (NaSSA) 3, 4:

• Blocks presynaptic α2-adrenergic autoreceptors and heteroreceptors, enhancing norepinephrine release 4
• Blocks postsynaptic 5-HT2 and 5-HT3 receptors while enhancing 5-HT1A-mediated serotonergic transmission 4
• This dual action may explain its relatively rapid onset of action compared to SSRIs 3

Common Side Effects

Most frequent adverse effects (significantly more common than placebo) 1, 4:

• Somnolence/sedation (19-23% vs 5-14% placebo) - often beneficial for patients with insomnia
• Increased appetite and weight gain (10-11% vs 1-2% placebo)
• Dry mouth (25% vs 16% placebo)
• Dizziness
• Constipation

Advantages over SSRIs:

• No sexual dysfunction - a major differentiator from SSRIs 4
• Fewer anticholinergic, cardiac, and neurological adverse events compared to tricyclic antidepressants 5

Serious but rare adverse effects:

• Agranulocytosis and neutropenia - monitor for signs of infection 5
• Serotonin syndrome when combined with other serotonergic medications 2, 1

Contraindications and Precautions

Absolute contraindications:

• Known hypersensitivity to mirtazapine 1
• Concomitant use with MAOIs or within 14 days of MAOI discontinuation 1
• Wait at least 14 days after stopping mirtazapine before starting an MAOI 1

Use with caution in:

• Liver or kidney disease (dose reduction required) 1
• Heart problems 1
• History of seizures or convulsions 1
• Bipolar disorder or mania 1
• Pregnancy and breastfeeding (drug passes into breast milk) 1

Drug interactions to avoid:

• Triptans, tramadol, SSRIs, SNRIs, tricyclics, lithium, St. John's Wort, tryptophan - risk of serotonin syndrome 1
• Alcohol and diazepam - may impair cognitive/motor performance 1

Medications affecting mirtazapine levels:

• Cimetidine and ketoconazole increase mirtazapine levels 1
• Phenytoin, carbamazepine, and rifampicin decrease mirtazapine levels 1

Clinical Advantages

Mirtazapine offers specific therapeutic benefits:

• Rapid onset of action - may work faster than SSRIs 3, 4
• Beneficial for depression with comorbid anxiety and sleep disturbance 4
• Useful when weight gain is desired (e.g., cancer patients, elderly with poor appetite) 6
• Effective for chronic insomnia in older adults - recent 2025 trial showed significant reduction in Insomnia Severity Index scores 7
• Safe in overdose with very low seizure potential 8, 5

Common Pitfalls to Avoid

• Do not stop abruptly - always taper gradually to avoid withdrawal symptoms 1
• Do not combine with MAOIs - absolute contraindication with 14-day washout period required 1
• Monitor for infection signs in early treatment due to rare agranulocytosis risk 5
• Avoid in patients where sedation or weight gain would be problematic unless these effects are therapeutically desired 1
• Do not drive or operate machinery until you know how the medication affects you, especially initially 1